1. Home
  2. GANX vs AUID Comparison

GANX vs AUID Comparison

Compare GANX & AUID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • AUID
  • Stock Information
  • Founded
  • GANX 2017
  • AUID 2009
  • Country
  • GANX United States
  • AUID United States
  • Employees
  • GANX N/A
  • AUID N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • AUID Computer Software: Prepackaged Software
  • Sector
  • GANX Health Care
  • AUID Technology
  • Exchange
  • GANX Nasdaq
  • AUID Nasdaq
  • Market Cap
  • GANX 45.8M
  • AUID 51.8M
  • IPO Year
  • GANX 2021
  • AUID N/A
  • Fundamental
  • Price
  • GANX $1.94
  • AUID $5.66
  • Analyst Decision
  • GANX Strong Buy
  • AUID
  • Analyst Count
  • GANX 5
  • AUID 0
  • Target Price
  • GANX $8.20
  • AUID N/A
  • AVG Volume (30 Days)
  • GANX 314.5K
  • AUID 232.2K
  • Earning Date
  • GANX 05-13-2025
  • AUID 05-13-2025
  • Dividend Yield
  • GANX N/A
  • AUID N/A
  • EPS Growth
  • GANX N/A
  • AUID N/A
  • EPS
  • GANX N/A
  • AUID N/A
  • Revenue
  • GANX N/A
  • AUID $886,485.00
  • Revenue This Year
  • GANX N/A
  • AUID N/A
  • Revenue Next Year
  • GANX N/A
  • AUID N/A
  • P/E Ratio
  • GANX N/A
  • AUID N/A
  • Revenue Growth
  • GANX N/A
  • AUID 365.86
  • 52 Week Low
  • GANX $0.89
  • AUID $4.01
  • 52 Week High
  • GANX $3.19
  • AUID $12.31
  • Technical
  • Relative Strength Index (RSI)
  • GANX 54.26
  • AUID 43.10
  • Support Level
  • GANX $1.85
  • AUID $5.80
  • Resistance Level
  • GANX $2.27
  • AUID $9.58
  • Average True Range (ATR)
  • GANX 0.16
  • AUID 1.14
  • MACD
  • GANX 0.02
  • AUID -0.27
  • Stochastic Oscillator
  • GANX 59.17
  • AUID 5.72

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About AUID authID Inc.

AuthID Inc is a company engaged in ensuring cyber-savvy enterprises "Know Who's Behind the Device" for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric passwordless authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.

Share on Social Networks: